Clinical trial tests promising CAR T-cell therapy for lupus

Overview

UCI Health is conducting a clinical trial of FT819, a novel CAR T-cell therapy for patients with moderate to severe systemic lupus erythematosus who have not responded to standard treatments. Early results indicate significant symptom reversal and improved function in participants, suggesting potential for long-term remission.

Background

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can lead to severe health complications and significantly impact quality of life. Traditional therapies often fail to provide adequate relief for patients with moderate to severe forms of the disease. Innovative treatments like CAR T-cell therapy represent a new frontier in managing refractory cases of SLE.

Data Highlights

No numerical data available in the source material.

Key Findings

• FT819 CAR T-cell therapy does not require harvesting and reprogramming of patient cells, reducing preparation time.
• One participant experienced a dramatic reversal of symptoms after nearly two decades of severe disease.
• The trial is part of a broader investigation into CAR T-cell therapies for autoimmune diseases.
• Current guidelines for lupus treatment emphasize immunosuppression and biologics, with CAR T-cell therapy still considered investigational.
• Related studies show promising results for CD19 CAR T-cell therapies in refractory SLE.

Clinical Implications

The findings from the FT819 trial may offer new hope for patients with refractory SLE, potentially leading to long-term remission without the need for extensive cell manipulation. Clinicians should remain informed about emerging therapies and consider participation in clinical trials for eligible patients.

Conclusion

The ongoing investigation of FT819 CAR T-cell therapy highlights a significant advancement in the treatment of systemic lupus erythematosus, with early results suggesting a potential shift in therapeutic approaches for this challenging condition.

References

1. UCI Health, UCI Health lupus clinical trial offers hope to patients with the disease, 2025 -- Clinical trial tests promising CAR T-cell therapy for lupus
2. Nature Medicine, CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial, 2026 -- Recent trials show promise for CAR T in SLE
3. PubMed, 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis, 2024 -- Current guidelines for lupus treatment
4. The ASCO Post — CAR T-Cell Therapy Promising in Non-Hodgkin Lymphoma CAR T Cells for Lymphoma
5. The ASCO Post — CAR T-Cell Therapy Promising in Non-Hodgkin Lymphoma CAR T Cells for Lymphoma
6. The ASCO Post — Update on CAR T-Cell ‘Breakthrough’ Therapy in Lymphoma
7. FT819 - Fate Therapeutics
8. Study Details | NCT06308978 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
9. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis - PubMed
10. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial | Nature Medicine
11. In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus - PubMed
12. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission - ScienceDirect
13. iPSC-Derived, Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with
14. FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies | FDA